HK Stock Market Move | LEADS BIOLABS-B(09887) last-minute gain nearly 3%, Dianthus is advancing the clinical development of LBL-047.

LEADS BIOLABS-B(09887) rose nearly 3% at the close of trading, rising 2.65% to HK$81.3 as of press time, with a turnover of HK$49.5042 million. On the news front, recently, LEADS BIOLABS-B announced that its partner, Dianthus Therapeutics (Dianthus, NASDAQ code: DNTH), has selected Sjgren's syndrome (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (DNTH212, the development code for Greater China). As a core pipeline asset of strategic importance, Dianthus is advancing the clinical development of LBL-047 to validate its clinical value in the three indications with high unmet needs in SjD, SLE, and DM. In March 2026, Dianthus successfully completed a large-scale underwritten public offering, raising approximately USD$719 million to provide strong capital support for the global development of LBL-047.